Targeted Assessment of participants through Recall by Genotype for Evaluation and Translation
This study leverages genomic information to identify individuals with high genetic risk for type 2 diabetes, assess their disease progression and healthcare utilization, and characterize their physiologic and pharmacogenetic responses to type 2 diabetes therapies.
Learn more about TARGET →
CGM-A1c Genetics
GWAS have identified over 200 hemoglobin A1c (HbA1c)-associated genetic variants, many of which affect HbA1c levels independently of glucose. This study examines whether these variants contribute to discordance between HbA1c and glucose measured by continuous glucose monitoring.
Learn more about CGM-A1c Genetics →
Diabetes Genetics & COVID-19 Severity
This research examines diabetes-related complications in acute COVID-19 illness, including new and persistent hyperglycemia, diabetic ketoacidosis, and severe insulin resistance, and their relationship to genetic and cardiometabolic risk factors.
Learn more about COVID →
PhaRmacogenetics Of the Glycemic RESponse to SGLT2 Inhibitors
PROGRESS is studying dapagliflozin (Farxiga) to understand the role of a patient’s genetic makeup in choosing what diabetes drug to prescribe. It’s one of the first pharmacogenetic investigations of SGLT2 inhibitors involving the acute response.
Learn more about PROGRESS →
Polygenic Assessment and Autoimmunity Testing for Health-System Screening of Type 1 Diabetes
This study uses a polygenic risk score to identify adults at increased genetic risk for type 1 diabetes and invites them for islet autoantibody screening, supporting earlier detection of presymptomatic autoimmune diabetes.
Learn more about PATHS-T1D →
Polygenic Assessment and Testing of Heterogeneity and Subtypes in Type 2 Diabetes
This study examines whether genetically defined subtypes of type 2 diabetes correspond to differences in physiology and treatment response, laying the groundwork for more individualized care.
Learn more about PATHS-T2D →